A Phase 3, Comparative Study of Asunaprevir and Daclatasvir (DUAL) Combination Therapy Versus Telaprevir Therapy in Japanese Genotype 1b Chronic Hepatitis C IFN Eligible-naive Subjects With a Single Arm Assessment of DUAL Therapy in IFN-therapy Relapsers
A Phase 3, Comparative Study of Asunaprevir and Daclatasvir (DUAL) Combination Therapy Versus Telaprevir Therapy in Japanese Genotype 1b Chronic Hepatitis C IFN Eligible-naive Subjects With a Single Arm Assessment of DUAL Therapy in IFN-therapy Relapsers
The purpose of this study is to assess the anti-viral activity of BMS-790052 and BMS-650032 combination therapy in Japanese subject.
The purpose of this study is to compare the anti-viral activity of the co-administration of Asunaprevir (ASV) and Daclatasvir (DCV) to Telaprevir (TVR) included therapy in Japanese Hepatitis C virus (HCV) subjects
Intervention Model: Parallel in the Naive cohort and Single group in the Relapser cohort
Inclusion Criteria:
Exclusion Criteria:
Patients who have;
Toyoake Shi, Aichi-ken 4701192, Japan
Ogaki-shi, Gifu 5038502, Japan
Obihiro-shi, Hokkaido 080-0016, Japan
Kawasaki-shi, Kanagawa 2138587, Japan
Osaka-sayama-shi, Osaka 5898511, Japan
Suita-shi, Osaka 5650871, Japan
Iruma-gun, Saitama 3500495, Japan
Shimotsuke-shi, Tochigi 3290498, Japan
Bunkyo-ku, Tokyo 1138519, Japan
Bunkyo-ku, Tokyo 1138655, Japan
Minato-ku, Tokyo 1058470, Japan
Musashino-shi, Tokyo 1808610, Japan
Shinagawa-ku, Tokyo 1428666, Japan
Chuo-shi, Yamanashi 4093898, Japan
Nishinomiya-shi, 6638501, Japan